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Neurotrophic factors are critical regulators of the formation and plasticity of neuronal networks. Brain-derived neurotrophic factor (BD-
NF) is abundant in the brain and periphery, and is found in both human serum and plasma. Animal studies have demonstrated that stress 
reduces BDNF expression or activity in the hippocampus and that this reduction can be prevented by treatment with antidepressant drugs. 
A similar change in BDNF activity occurs in the brain of patients with major depression disorder (MDD). Recently, clinical studies have 
indicated that serum or plasma BDNF levels are decreased in untreated MDD patients. Antidepressant treatment for at least four weeks 
can restore the decreased BDNF function up to the normal value. Therefore, MDD is associated with impaired neuronal plasticity. Suicidal 
behavior can be a consequence of severe impaired neuronal plasticity in the brain. Antidepressant treatment promotes increased BDNF ac-
tivity as well as several forms of neuronal plasticity, including neurogenesis, synaptogenesis and neuronal maturation. BDNF could also play 
an important role in the modulation of neuronal networks. Such a neuronal plastic change can positively influence mood or recover depressed 
mood. These alterations of BDNF levels or neuronal plasticity in MDD patients before and after antidepressant treatment can be measured 
through the examination of serum or plasma BDNF concentrations. BDNF levels can therefore be useful markers for clinical response or 
improvement of depressive symptoms, but they are not diagnostic markers of major depression.  Psychiatry Investig 2010;7:231-235
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INTRODUCTION
Major depressive disorder (MDD) is a common psychiatric 
mood disorder; mood disorders are episodic illnesses. MDDs 
consist of a single episode or several instances of recurrent or 
relapsed episodes of major depression. The pathophysiology 
of major depression can involve reversible changes. Recent 
reports have proposed that major depressive episodes and any 
subsequen recovery are associated with neuronal plasticity. 
Preclinical and clinical studies demonstrate that reductions 
of the total volume of neurons and neuronal loss occur in stress 
and depression in the adult hippocampus.
1 These hippocampal 
alterations can be reversed by chronic antidepressant treat-
ment.
1 The associated neuronal plasticity involves actions of 
neurotrophic factors, such as brain-derived neurotrophic 
factor (BDNF). 
BDNF is an important neurotrophic factor. Its function is 
mediated by its binding to specific receptors, such as the TrkB 
receptor among the tropomycin receptor kinase (Trk) family 
of tyrosine kinase receptors and the pan75 neurotrophin re-
ceptor (p75
NTR). Neurotrophic factors act in the activity-de-
pendent manner of a neuronal network. BDNF expression is 
closely regulated by neuronal activity.
2 Localization of the TrkB 
receptor also increases at synaptic sites after neuronal activity.
3 
p75
NTR is a low-affinity receptor of BDNF, and it can mediate 
neuronal apoptosis only when the Trk receptor is less active or 
not active.
4 
The neurotrophic hypothesis of depression proposes that 
depression is associated with reduced brain BDNF levels and 
that antidepressant treatments alleviate depressive behavior 
and increase BDNF levels.
5 This alteration was recently expl-
ained as activity-dependent neuronal plasticity.
6 In this study, 
we focused on recent findings regarding the role of BDNF in 
the occurrence and improvement of MDD and suicide, and we 
summarized findings of blood cell studies of BDNF. 
BDNF AND STRESS IN ANIMAL STUDIES
Animal studies have shown that BDNF expression is dys-232  Psychiatry Investig 2010;7:231-235
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regulated by stress. Several types of stressors, including im-
mobilization stress, foot shocks, social defeat, and early ma-
ternal deprivation, significantly decrease BDNF expression in 
the hippocampus, especially in the dentate gyrus.
7-11 In partic-
ular, stressors such as forced swimming reduced BDNF mes-
senger RNA (mRNA) in the hippocampus, and the physical ac-
tivity-antidepressant treatment combinations enhanced swimm-
ing time and increased BDNF mRNA in an animal model.
12 
Several studies have found that exogenous corticosterone 
treatment reduces hippocampal BDNF expression.
13,14 In con-
trast, adrenalectomy increases the level of BDNF in the hippo-
campus.
15 These findings indicate that hippocampal BDNF 
expression is regulated via glucocorticoids. Moreover, antide-
pressant treatments can prevent stress-induced reduction of BD-
NF,
16 and they can restore the corticosterone-mediated decre-
ase in BDNF expression.
14 Therefore, stressors stimulate the ac-
tivity of the hypothalamic-pituitary-adrenal axis, and then glu-
cocorticoids increase, which can reduce the activity of BDNF. 
BDNF AND ANTIDEPRESSANT 
TREATMENT IN ANIMAL STUDIES
Several classes of antidepressants, including monoamine oxi-
dase inhibitors (MAOIs), selective serotonin reuptake inhibi-
tors (SSRIs), tricyclic agents (TCAs), serotonin-norepinephrine 
reuptake inhibitors (SNRIs), and noradrenergic and specific se-
rotonergic antidepressants, increase BDNF expression in the 
brain when given to healthy rodents.
17 Electroconvulsive shock 
(ECS) and transcranial magnetic stimulation also increase the 
expression of BDNF in the rodent brain.
18,19 Another experi-
ment investigated the effects of acute and chronic treatment 
with different antidepressant agents and ECS on protein lev-
els of BDNF in several brain regions of the rat.
20 Chronic (21 days) 
but not acute (1 day) antidepressant treatment with TCAs, SS-
RIs and MAOIs increased BDNF levels in the frontal cortex 
by 10-30%. Chronic MAOI use increased BDNF to a greater 
extent than treatment with the other classes of agents. Repeat-
ed daily treatments (10 days) of ECS enhanced BDNF levels in 
the hippocampus and frontal cortex by 40-100%, but one ECS 
treatment (1 day) was not as effective.
20 However, the effect of 
ECS was higher in magnitude compared to the effects of sev-
eral antidepressant drugs. Various factors that influence this 
antidepressant effect on BDNF include length of administra-
tion, route of administration, class of antidepressant, and doses 
of the drugs. In general, increases in BDNF expression appear 
only after long-term treatment with antidepressants.
21-23 
Chronic antidepressant administration may induce plastic 
changes in the forebrains of rodents.
17 Antidepressant treatments 
can also increase neurogenesis and synaptogenesis in the hip-
pocampus.
1,24 Chronic antidepressant treatment additionally 
increases the expression of plasticity-related proteins, includ-
ing phosphorylated the cyclic adenosine monophosphate re-
sponse element binding protein (CREB) and polysialylated neu-
ral cell adhesion molecules, in the hippocampus and prefrontal 
cortex.
25 These findings indicate that antidepressant treatment 
can increase neuronal plasticity in the brain. 
Antidepressant treatment can also modulate chromatin re-
modeling, which regulates the activity of gene transcription. 
When histone subunits surround chromosomal DNA, methyl-
ation of histone subunits reduces gene transcription, whereas 
their acetylation enhances transcription. Antidepressant treat-
ment can induce acetylation of histone subunits around the BD-
NF gene promoter region and lead to increased BDNF gene tr-
anscription and increased BDNF production.
16
Wild-type mice that were given antidepressant agents ex-
perienced increased phosphorylation of CREB as well as phos-
phorylation of TrkB in the brain.
26 When antidepressants were 
given to BDNF-deficient mice or Trk-defective mice, activa-
tions of CREB and Trk were reduced in BDNF-deficient or Trk-
defective mice. In addition, the behavioral effects of antidepres-
sants did not occur in BDNF-deficient mice or Trk-defective 
mice.
26,27 BDNF-deficient mice have 50% lower forebrain BD-
NF mRNA and protein levels than the wild type mice.
28 How-
ever, BDNF-deficient mice do not have reduced activity or 
response to the forced swim test compared to the wild-type 
mice.
29 Trk-defective mice also do not exhibit depression-like 
behaviors.
30 Therefore, a deficiency or dysfunction of BDNF or 
the Trk receptor cannot induce depressed mood or behavior; 
BDNF itself does not control mood. However, the antidepres-
sant response clearly requires an increase of BDNF activity and 
recovery of the neuronal network. A neuronal plastic change 
could positively influence mood or recover depressed mood. 
BDNF could also play an important role in the modulation of 
neuronal networks. 
BDNF AND MAJOR DEPRESSION 
IN CLINICAL STUDIES
Previous human postmortem studies showed decreased BD-
NF expression or CREB immunoreactivity in the brains of par-
ticipants with major depression who had not been treated with 
antidepressants, but those who were treated with antidepres-
sant drugs had increased BDNF expression and CREB in the 
brain.
31,32 These data are consistent with those of the aforemen-
tioned animal studies. 
Recent clinical studies have explored serum or plasma BD-
NF levels in patients with major depression. Though the source 
of the circulating BDNF is not clear, BDNF is found in both hu-
man serum and plasma, and a large amount of the circulating 
BDNF is stored in human platelets as well.
33 BDNF can cross BH Lee & YK Kim 
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the blood-brain barrier in both directions, and the circulating 
BDNF could originate from neurons of the brain.
34,35 Some 
clinical studies that measured serum BDNF levels in drug-free 
MDD patients have shown that serum BDNF levels are signif-
icantly lower in MDD patients than in healthy participants.
36-39 
Other studies reported that plasma BDNF levels are lower in 
drug-free MDD patients.
38,40 However, there have been incon-
sistent findings of the relationship between BDNF levels and 
the severity of depression from these data. Some studies sug-
gested a more significant decrease of BDNF in more severe 
depression. Though our data did not demonstrate any relation-
ship between BDNF and depression severity, we found that 
relapsed or recurrent-episode MDD patients had much lower 
plasma BDNF levels than first-onset ones.
40 
Many clinical studies have evaluated the changes of plasma 
or serum BDNF levels before and after antidepressant treat-
ments among MDD patients. Most studies reported increas-
es of BDNF levels after antidepressant treatment.
41 Two studies 
observed that both SSRI and SNRI treatments for eight weeks 
increased serum BDNF levels in MDD patients.
36,42 However, 
another study reported that SSRI agents increased serum BD-
NF levels after six months, but that the SNRI agent did not ch-
ange the level of BDNF even after six months of treatment.
43 
Additional clinical reports found that plasma and serum BDNF 
levels in MDD patients increased after six or eight weeks of 
antidepressant drug treatments.
42,44 These studies suggest that 
the antidepressant-induced increase in BDNF level is more pro-
minent in the responders to treatment rather than the non-res-
ponders.
42,44 A meta-analysis indicated that post-treatment BD-
NF levels may be useful since four to eight weeks of antidepres-
sant treatment are recommended to evaluate a change of BDNF 
or a treatment effect.
41 Another recent study investigated changes 
of serum and plasma from MDD patients at baseline and fol-
lowing the first, third, sixth, and twelfth month of antidepres-
sant treatment.
45 MDD patients had lower serum and plasma 
BDNF levels before treatment. Plasma BDNF increased in par-
allel with the clinical improvement from the one-month eval-
uation, while serum BDNF had no change after treatments. 
These data of clinical studies of antidepressant treatment are 
consistent with those of animal studies on the effects of anti-
depressants on BDNF changes. Therefore, it is possible that 
serum or plasma levels of BDNF reflect the state of the neuro-
nal network in patients with major depression. MDD patients 
can have decreased BDNF levels before treatment, which can 
be restored to the normal level through antidepressant treat-
ment or by improving neuronal plasticity. 
BDNF AND SUICIDAL BEHAVIOR
Postmortem studies show that mRNA expression and pro-
tein levels of BDNF are reduced in the brains of patients with 
major depression who commit suicide.
46,47 The expression of 
full-length TrkB or truncated TrkB (TrkB.T1) is significantly 
decreased in the brains of suicide patients in postmortem st-
udies.
47,48 A recent study observed decreased phosphorylation 
of Trk receptors and increased expression ratios of p75
NTR to 
Trks in the suicide patient’s brain.
49 These changes were partic-
ularly apparent in the prefrontal cortex and the hippocampus. 
Clinical studies have examined BDNF levels in serum or pla-
sma of MDD patients who have or have not attempted suicide. 
MDD patients who attempted suicide had lower serum BD-
NF levels than healthy controls.
50 Our study found that plas-
ma BDNF was significantly lower in suicidal MDD patients 
than in non-suicidal ones.
40,51 Moreover, suicidal patients had 
the lowest levels of BDNF of all participants.
40 We failed to find 
any correlation between BDNF level and the lethality of sui-
cide.
51 Dawood et al.
52 took direct blood samples from the in-
ternal jugular vein and the brachial artery and then defined the 
veno-arterial BDNF plasma concentration gradient as an in-
dex of brain BDNF production. Their data showed a signifi-
cantly decreased veno-arterial BDNF concentration gradient 
in patients at higher suicide risk among MDD participants. 
These changes of serum or plasma BDNF levels in suicide 
patients are consistent with BDNF changes of the brain in post-
mortem studies on patients who died following suicide. There-
fore, the phenomenon of suicidal behavior could be a conse-
quence of a severe dysfunction of the neuronal network or of 
severely impaired neuronal plasticity in the brain compared to 
MDD patients. 
CONCLUSIONS
BDNF is involved in activity-dependent neuronal plastici-
ty, such as learning and memory.
53 Although animal studies 
clearly demonstrate that a decline of BDNF does not produce 
depressed mood or behavior, evidence from clinical studies 
tells us that decreased activity of BDNF or a neuronal dys-
function occurs in the brain of patients with major depres-
sion. Major depression is associated with impaired neuronal 
plasticity. Suicidal behavior can be a consequence of severely 
impaired neuronal plasticity in the brain. Antidepressant treat-
ments promote several forms of neuronal plasticity, includ-
ing neurogenesis, synaptogenesis and neuronal maturation 
and also increase BDNF activity, which can develop the anti-
depressant response. Figure 1 represents these effects of neu-
ronal plasticity or BDNF on major depression, antidepressant 
treatment, and suicide behavior. BDNF could play an impor-
tant role in the modulation of neuronal networks. Such neu-
ronal plastic change can positively influence mood or recover 
depressed mood. These alterations of BDNF levels or neuro-234  Psychiatry Investig 2010;7:231-235
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nal plasticity in MDD patients before and after antidepres-
sant treatment can be measured through serum or plasma 
BDNF concentrations. BDNF levels in serum or plasma will 
be useful markers for clinical response or improvement of de-
pressive symptoms rather than a diagnostic marker of major 
depression. 
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